Advanced

Imaging apolipoprotein AI in vivo

Sriram, Renuka; Lagerstedt, Jens LU ; Petrlova, Jitka; Samardzic, Haris; Kreutzer, Ulrike; Xie, Hongtao; Kaysen, George A.; Desreux, Jean F.; Thonon, David and Jacques, Vincent, et al. (2011) In NMR in Biomedicine 24(7). p.916-924
Abstract
Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach... (More)
Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo. Copyright (C) 2011 John Wiley & Sons, Ltd. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
NMR, apolipoprotein, HDL, contrast agent, MRI, gadolinium, cardiovascular risk
in
NMR in Biomedicine
volume
24
issue
7
pages
916 - 924
publisher
John Wiley & Sons
external identifiers
  • wos:000294686900019
  • scopus:80051581209
ISSN
0952-3480
DOI
10.1002/nbm.1650
language
English
LU publication?
yes
id
2adc16c8-5aeb-4cd2-8c62-06ecdffd285b (old id 2186757)
date added to LUP
2011-11-01 07:51:09
date last changed
2017-01-01 03:25:10
@article{2adc16c8-5aeb-4cd2-8c62-06ecdffd285b,
  abstract     = {Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo. Copyright (C) 2011 John Wiley & Sons, Ltd.},
  author       = {Sriram, Renuka and Lagerstedt, Jens and Petrlova, Jitka and Samardzic, Haris and Kreutzer, Ulrike and Xie, Hongtao and Kaysen, George A. and Desreux, Jean F. and Thonon, David and Jacques, Vincent and Van Loan, Martha and Rutledge, John C. and Oda, Michael N. and Voss, John C. and Jue, Thomas},
  issn         = {0952-3480},
  keyword      = {NMR,apolipoprotein,HDL,contrast agent,MRI,gadolinium,cardiovascular risk},
  language     = {eng},
  number       = {7},
  pages        = {916--924},
  publisher    = {John Wiley & Sons},
  series       = {NMR in Biomedicine},
  title        = {Imaging apolipoprotein AI in vivo},
  url          = {http://dx.doi.org/10.1002/nbm.1650},
  volume       = {24},
  year         = {2011},
}